Managed Account Advisors’s Alder Biopharmaceuticals ALDR Stock Holding History

Managed Account Advisors’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$3.9M	Sell	73,715 -1,677	-2%	-$61K	﹤0.01%	1536
2015 Q1	$2.18M	Buy	75,392 +74,963	+17,474%	+$2.06M	﹤0.01%	1810
2014 Q4	$12K	Sell	429 -21	-5%	-$377	﹤0.01%	2616
2014 Q3	$6K	Sell	450 -3	-0.7%	-$45	﹤0.01%	2623
2014 Q2	$9K	Buy	+453	New	+$6.38K	﹤0.01%	2583

Other funds holding ALDR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Managed Account Advisors's ALDR Position: Q2 2015 in Review

Managed Account Advisors reduced its Alder Biopharmaceuticals (ALDR) stake by 2.2% in Q2 2015, selling an estimated $61K and leaving 73,715 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1536.

Managed Account Advisors first reported a position in ALDR in Q2 2014 and has held it in 5 quarters since. 127 funds tracked by Wall St. Rank hold ALDR as of Q2 2015.

Managed Account Advisors held 73,715 shares of Alder Biopharmaceuticals worth $3.9M as of Q2 2015.
Managed Account Advisors sold 1,677 Alder Biopharmaceuticals shares in Q2 2015, an estimated $61K.
Alder Biopharmaceuticals made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #1536 holding.
Managed Account Advisors first reported a position in Alder Biopharmaceuticals in Q2 2014 and has held it in 5 quarters since.
127 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.